WNT5A and type 2 diabetes mellitus: sFRP5 is an anti‐inflammatory adipokine that exerts a promising therapeutic effect on inflammatory diseases, including obesity and T2DM, via antagonizing the non‐canonical Wnt5a signalling pathway, and the exact roles of sFRP5 in the pathogenesis of these diseases have been systematically outlined by Shen et al.142